Research programme: mRNA vaccines - Vaxess Technologies
Latest Information Update: 27 Apr 2023
At a glance
- Originator Vaxess Technologiess
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 25 Apr 2023 Pharmacodynamics data from preclinical studies in COVID-2019 infections released by Vaxess Technologiess
- 01 Mar 2022 Vaxess Technologiess plans a phase I trial for COVID-2019 infections (Prevention) in 1H 2022 (Transdermal)
- 22 Apr 2021 Vaxess Technologiess announces intention to submit IND application to the US FDA for COVID-2019 infections (Prevention) in 2021 (Transdermal)